Yu Liu

Yu Liu

Auto-generated profile, based on publicly available information

Yu Liu

Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MWMeiyu Wang
Meiyu Wang
PFPing Fu
Ping Fu
YYYonghua Yin
Yonghua Yin
MHMiao He
Miao He
YLYu Liu
Yu Liu
Hepatitis E virus is one of new threats to blood safety which was usually considered to be transmitted via fecal-oral route. China is one of the hyperendemic regions where frequent outbreaks of hepatitis E are noted. However, the overall prevalence of HEV infection among mainland Chinese blood donors is not clear until now. The peer-reviewed literatures reporting the prevalence of HEV in Chinese blood donors were identified by systematic searching of five electronic databases. The systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement issued in 2009. Data manipulation and statistical analyses were performed by Stata 12.0. Fourteen eligible articles involving 22 independent studies were included. Pooled prevalence of HEV infection biomarkers (anti-HEV IgG, anti-HEV IgM, RNA and antigen) among mainland Chinese blood donors were 29.2%, 1.1%, 0.1% and 0.1%, respectively which were higher than the data reported in other countries. The analysis of HEV genotypes indicated that the most prevalent strains in Chinese blood donors were genotype 1 and 4. Mainland China is indicated with a relatively higher risk of transmission of hepatitis E through transfusion and the screening of blood donors for HEV RNA, especially in HEV-endemic areas, might reduce the potential risk of HEV infection via transfusion.

14 May 2015 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YZYa Zhou
Ya Zhou
GBGuohui Bian
Guohui Bian
QZQiongxiu Zhou
Qiongxiu Zhou
ZGZhan Gao
Zhan Gao
PLPu Liao
Pu Liao
MHMiao He
Miao He

16 June 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PZPeibin Zeng
Peibin Zeng
YLYu Liu
Yu Liu
MHMiao He
Miao He
JWJingxing Wang
Jingxing Wang
SKSheila Keating
Sheila Keating
OPon behalf of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III program
on behalf of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III program
The increasing complexity and diversity of the human immunodeficiency virus-1 (HIV-1) infections challenge the disease control and anti-retrovirus treatment in China. The infection stages and molecular characteristics of HIV-1 from infected Chinese blood donors were examined to shed light on the HIV genotype distribution and the status of drug resistance mutations (DRMs) in the changing HIV epidemic in China. Western blot (WB) confirmed HIV-1 positive plasma samples were collected from blood donors at five Chinese blood centers from April 16, 2012, through June 30, 2014. The HIV infection stages were determined using the Lag-avidity assay. HIV Pol regions including whole protease and partial reverse transcriptase (RT) were amplified and sequenced to establish the profile of genotype distribution and drug resistance mutations (DRMs). Viral loads were determined using the ROCHE COBAS system. Of the 259 HIV-1 positive samples tested by the Lag-avidity assay, 23.6% (61/259) were identified as recent infections. A total of 205 amplified sequences displayed the following genotype distributions: circulating recombinant form (CRF) 07_BC (61.5%), CRF08_BC (8.3%), CRF01_AE (20%), B (6.3%), and 01B (3.9%). There was no significant difference in genotype distribution between recent and long-term infections. 31 DRMs were identified from 27 samples including four protease inhibitors (PIs) accessory DRMs, two PIs major DRMs (M46I), two nucleoside RT inhibitors DRMs (K219R and K70Q), and 23 nonnucleoside RT inhibitors DRMs. 27 samples had DRMs, yielding a drug resistance prevalence of 13.2% (27/205). Our findings provide important information for developing strategies for comprehensive HIV control and improving anti-retroviral treatment in China.

14 February 2017 in Transfusion
Verified
Journal Article
Closed access
PDF file
MWMeiyu Wang
Meiyu Wang
MHMiao He
Miao He
BWBinting Wu
Binting Wu
LKLing Ke
Ling Ke
THTingting Han
Tingting Han
KNKenrad E. Nelson
Kenrad E. Nelson

16 October 2019 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
PFPing Fu
Ping Fu
SDSushil Devare
Sushil Devare
JLJian‐Fang Liu
Jian‐Fang Liu
XLXiao‐Ting Lv
Xiao‐Ting Lv
PYPeng Yin
Peng Yin
HSHua Shan
Hua Shan
Background and Objectives: To prevent Treponema Pallidum (TP) transmission from blood transfusion, enzyme‐linked immunosorbent assay (EIA) for anti‐TP has been widely used in routine blood donation screening in China for many years. The aim of this study was to evaluate the performance of the Abbott CMIA assay for detection of anti‐TP in Chinese blood donors. Materials and methods: A total of 2420 plasma samples, already routinely screened for anti‐TP by two different EIAs, from four blood Centers were tested for anti‐TP by Abbott CMIA. Subsequently, all samples with positive results by one or both EIAs and/or by Abbott CMIA were subjected to confirmatory testing (CT) using recombinant immunoblot assay (RIBA) or Treponema Pallidum particle agglutination assay (TPPA). TP infection was defined by a RIBA or TPPA positive. Results: Compared with two EIAs strategy, Abbott CMIA showed a relatively best sensitivity as 98.80% (95% CI: 97.44%‐100.16%) and a relatively best specificity as 99.58% (95% CI: 99.30%‐99.85%), yielding the best consistency (99.49%) between anti‐TP CT results with the highest κ value of .98. Conclusion: This is the first study to evaluate the performance of the Abbott CMIA assays for detection of syphilis in Chinese blood donors. Our results suggested that CMIA performed better than both EIAs, and implementation of CMIA replacing two different EIA reagents might help to further reduce the risk of transfusion‐transmitted TP infection, decrease unnecessary blood waste and loss of blood donors.

31 July 2017 in Transfusion Medicine
Verified
Journal Article
Closed access
PDF file
ZGZ. Gao
Z. Gao
YZY. Zhang
Y. Zhang
YYY. Yang
Y. Yang
MXM. Xu
M. Xu
PLP. Liao
P. Liao
MHMiao He
Miao He